Hikma Pharmaceuticals (CHIX:HIKL) EPS (Basic): £1.35 (TTM As of Dec. 2025)


CHIX:HIKL Hikma Pharmaceuticals PLC CHIX:HIKL
80 GF Score
Price £15.11
GF Value £20.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals EPS (Basic)?

Hikma Pharmaceuticals CHIX:HIKL +1.96% 80 EPS (Basic) is £1.35 as of Dec. 2025. GuruFocus rates CHIX:HIKL with a GF Score™ of 80/100 and a GF Value™ of £20.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was £0.56. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was £1.35.

Hikma Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was £0.55. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £1.34.

Hikma Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was £0.78. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 1.68.

During the past 12 months, Hikma Pharmaceuticals's average EPS without NRIGrowth Rate was -3.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 4.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Hikma Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 59.40% per year. The lowest was -6.50% per year. And the median was 10.90% per year.

Hikma Pharmaceuticals  (CHIX:HIKl) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hikma Pharmaceuticals EPS (Basic) Related Terms

Hikma Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals EPS (Basic) Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 0.69 0.68 1.28 1.36

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.80 0.48 0.79 0.56
CHIX:HIKL
80GF Score
Hikma Pharmaceuticals PLC CHIX:HIKL
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hikma Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(300.294-0)/220.588
=1.36

Hikma Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(122.508-0)/220.107
=0.56

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of £1.35 mean?
Hikma Pharmaceuticals (CHIX:HIKL) has a EPS (Basic) of £1.35 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' EPS (Basic) too high?
Hikma Pharmaceuticals' current EPS (Basic) is £1.35. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EPS (Basic) compare to ZTS and UTHR?
Hikma Pharmaceuticals' EPS (Basic) of £1.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current EPS (Basic) is £1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (CHIX:HIKL) is currently considered Modestly Undervalued. The stock's GF Value™ is £20.99, compared to a current price of £15.11 — trading 28% below its estimated fair value. The current EPS (Basic) is £1.35. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hikma Pharmaceuticals (CHIX:HIKL), the current EPS (Basic) is £1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (CHIX:HIKL) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of £15.11 is trading 28% below its estimated GF Value™ of £20.99. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for CHIX:HIKL:

  • EPS (Basic): £1.35
  • GF Value™: £20.99 vs. price of £15.11 (28% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:HIKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score

Get the complete analysis for CHIX:HIKL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£15.11
Price
£20.99
GF Value